Native X-DING-CD4 protein secreted by HIV-1 resistant CD4+ T cells blocks activity of IL-8 promoter in human endothelial cells infected with enteric bacteria.
Onsets of bacterial infections devastate the compromised immune system in AIDS patients. Damaged gut mucosa permits dissemination of bacterial toxins into deeper layers and hyper-activation of the immune system. We previously reported that the unfractionated supernatants of HIV-resistant CD4(+) T cells impeded the NF-κB/DNA binding in macrophages induced by either HIV-1 or LPS. The active component of this soluble material was identified as X-DING-CD4 (extracellular DING from CD4 T cells). We hypothesized that the anti-inflammatory effect of the X-DING-CD4 protein might extend to non-immune cells, for example endothelial cells, undergoing persistent endotoxin stimulation in the course of advanced HIV disease. To test this proposition, we evaluated the efficiency of NF-κB and Ap-1 binding to the IL-8 promoter in LPS-activated endothelial cells and control human macrophages exposed to native X-DING-CD4 protein. We found a deficiency of NF-κB- but not AP-1-DNA binding in the systems where cells were treated with native soluble X-DING-CD4 protein. The X-DING-CD4-mediated inhibition of the IL-8 promoter also resulted in a reduction of the soluble IL-8 protein in endothelial cells and human macrophages infected with a subset of enteric bacteria frequently causing diarrhea in progressive HIV disease. Bacterial endotoxin did not induce the endogenous X-DING-CD4 mRNA activity in human macrophages and transformed CD4(+)T cells, indicating that the reduction of LPS-mediated IL-8 promoter activation was not related to de novo X-DING-CD4 protein synthesis, but depended on function of the exogenous X-DING-CD4 protein. This study provides evidence that the X-DING-CD4 protein might be developed as a novel biotherapeutic to control LPS-mediated inflammation in advanced HIV disease.
Protein Chemistry Laboratory, St. Luke's/Roosevelt Hospital, Columbia University, New York, NY 10019, USA.
Anna
A
Ivanova
Protein Chemistry Laboratory, St. Luke's/Roosevelt Hospital, Columbia University, New York, NY 10019, USA.
Rasheda Y
RY
Shilpi
Protein Chemistry Laboratory, St. Luke's/Roosevelt Hospital, Columbia University, New York, NY 10019, USA.
Rakhee
R
Sachdeva
Protein Chemistry Laboratory, St. Luke's/Roosevelt Hospital, Columbia University, New York, NY 10019, USA.
Guanhua
G
Li
Protein Chemistry Laboratory, St. Luke's/Roosevelt Hospital, Columbia University, New York, NY 10019, USA.
Malgorzata
M
Simm
D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D002461:Cell Line, Transformed; D003967:Diarrhea / Q000209:etiology / Q000276:immunology / Q000382:microbiology; D042783:Endothelial Cells / Q000276:immunology / Q000382:microbiology*; D005786:Gene Expression Regulation; D015658:HIV Infections / Q000235:genetics*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D016209:Interleukin-8 / Q000235:genetics*; D008070:Lipopolysaccharides / Q000378:metabolism; D008264:Macrophages / Q000276:immunology / Q000382:microbiology; D016328:NF-kappa B / Q000378:metabolism; D011401:Promoter Regions, Genetic / Q000235:genetics; D011485:Protein Binding / Q000276:immunology; D012480:Salmonella Infections / Q000209:etiology / Q000276:immunology* / Q000382:microbiology; D012486:Salmonella typhimurium; D018808:Transcription Factor AP-1 / Q000378:metabolism
D002352:Carrier Proteins; D016209:Interleukin-8; D008070:Lipopolysaccharides; D016328:NF-kappa B; D018808:Transcription Factor AP-1; C544193:X-DING-CD4 protein, human